Most relevant fly genus in equine IBH
Culicoides
Simulium are also important
Predominant feeding site of Culicoides pulicaris
Along the dorsal aspects of horses where lesions of IBH are common
Flying insects known to bite horse
Main feeding times of Culicoides
Dawn and dusk
Nine Culicoides antigens have
been identified as ‘major allergens’ in IBH
horses through studies focusing on IgE
binding from sera of affected horses - what are 8 of them?
Cul n 1 - 5
Cul o 1 -3
Other source: Cul o 1P, Cul o 2P, Cul o 3, Cul o 5, Cul o 7, Cul o 8 Cul o 9, Cul o 10, Cul o 11
Risk factors for the development of IBH
What types of hypersensitivity reactions have been implicated in IBH?
Key cytokine group involved in IBH
Th2 cytokines
Histologically, IBH is characterized by infiltration of which inflammatory cells?
Mast cells and eosinophils
some texts say lymphocytes > mast cells
What cells and inflammatory mediators are increased in the lesional skin of IBH horses
Which immunoglobulins have roles in IBH
IgE and IgG (5 and 1)
What transcription factor is reduced in IBH skin?
FOXP3
FOXP3 is regulatory - less regulation => more reaction
Target of monoclonal antibody therapy for horses with IBH
IL-5
Is early life or later in life exposure to Cullicoides associated with a greater predisposition to IBH
Later in life exposure
IBH lesion distribution
face (jaw, ears), neck, ventrum, inguinal region, mane, tail,
limbs
Primary therapeutic strategy for IBH
Risk factors for the development of IBH
Strategies to reduce Culicoides exposure
Horse breeds more commonly affected by atopic dermatitis
Th2 cytokines upregulated in equine AD
IL-4, IL-5, IL-6 and IL-13 and IL-31
Recommended medication withdrawal times prior to IDST in horses
minimum withdrawal times are:
14 days for oral glucocorticoids and
7 days for oral antihistamines
Main types of steroids used in equine AD management
Antihistamines most commonly used in the management of equine AD
Pentoxyfilline is sometimes used in combination with glucocorticoids for the management of equine AD. Proposed MOA in allergic skin conditions